Drug reference

Stiripentol

BNF 80 (2020–2021)

Source: BNF 80 (2020–2021)
PDF pages: 369

Review source pages for extracted sections and age labels. BNF dose snippets show only their first line.

Overview

Indications And Dose

Adjunctive therapy of refractory generalised tonic-clonic seizures in patients with severe myoclonic epilepsy in infancy (Dravet syndrome) in combination with clobazam and valproate (under expert supervision) ▶BY MOUTH ▶Adult: Doses of up to 50 mg/kg daily in 2–3 divided doses should be continued for as long as efﬁcacy is observed DOSE EQUIVALENCE AND CONVERSION ▶Stiripentol capsules and oral powder sachets are not bioequivalent. If a switch of formulation is required, manufacturer advises this is done under clinical supervision in case of intolerance.

PDF page 369

Contra Indications

History of psychosis in the form of episodes of delirium

PDF page 369

Allergy And Cross Sensitivity

Antiepileptic hypersensitivity syndrome theoretically associated with stiripentol. See under Epilepsy p. 321 for more information.

PDF page 369

National Funding Access Decisions

Scottish Medicines Consortium (SMC) decisions The Scottish Medicines Consortium has advised (September 2017) that stiripentol (Diacomit ®) is accepted for use within NHS Scotland in conjunction with clobazam and valproate as adjunctive therapy of refractory generalised tonic-clonic seizures in patients with severe myoclonic epilepsy in infancy whose seizures are not adequately controlled with clobazam and valproate. All Wales Medicines Strategy Group (AWMSG) decisions The All Wales Medicines Strategy Group has advised (November 2017) that stiripentol (Diacomit ®) is recommended for use within NHS Wales for use in conjunction with clobazam and valproate as adjunctive therapy of refractory generalized tonic-clonic seizures in patients with severe myoclonic epilepsy in infancy (SMEI, Nervous system Dravet syndrome) whose seizures are not adequately controlled with clobazam and valproate.

PDF page 369

Safety

Interactions

→Appendix 1: antiepileptics

PDF page 369

Side Effects

▶Common or very common Agitation. appetite decreased. behaviour abnormal. drowsiness. irritability. movement disorders. muscle tone decreased. nausea. neutropenia. sleep disorders. vomiting. weight decreased ▶Uncommon Diplopia. fatigue. photosensitivity reaction. skin reactions ▶Rare or very rare Thrombocytopenia

PDF page 369

Pregnancy

See also Pregnancy in Epilepsy p. 321. Monitoring The dose should be monitored carefully during pregnancy and after birth, and adjustments made on a clinical basis.

PDF page 369

Breast Feeding

Present in milk in animal studies.

PDF page 369

Hepatic Impairment

Manufacturer advises avoid (no information available).

PDF page 369

Renal Impairment

Avoid—no information available.

PDF page 369

Monitoring Requirements

Perform full blood count and liver function tests prior to initiating treatment and every 6 months thereafter.

PDF page 369

Dose and formulations

Medicinal Forms

There can be variation in the licensing of different medicines containing the same drug. Powder CAUTIONARY AND ADVISORY LABELS 1, 8, 13, 21 EXCIPIENTS: May contain Aspartame ▶Diacomit (Alan Pharmaceuticals) Stiripentol 250 mg Diacomit 250mg oral powder sachets | 60 sachet P £284.00 DT = £284.00 Stiripentol 500 mg Diacomit 500mg oral powder sachets | 60 sachet P £493.00 DT = £493.00 Capsule CAUTIONARY AND ADVISORY LABELS 1, 8, 21 ▶Diacomit (Alan Pharmaceuticals) Stiripentol 250 mg Diacomit 250mg capsules | 60 capsule P £284.00 DT = £284.00 Stiripentol 500 mg Diacomit 500mg capsules | 60 capsule P £493.00 DT = £493.00

PDF page 369

Dose text by age group

Adult

Doses of up to 50 mg/kg daily in 2–3 divided

First-line fragment. Read the complete Indications and Dose section above.

PDF page 369

Age labels are extracted for navigation. Check the complete source section and current local guidance before clinical use.

Drug reference

Stiripentol

BNF 80 (2020–2021)

Source: BNF 80 (2020–2021)
PDF pages: 369

Review source pages for extracted sections and age labels. BNF dose snippets show only their first line.

Overview

Indications And Dose

PDF page 369

Contra Indications

History of psychosis in the form of episodes of delirium

PDF page 369

Allergy And Cross Sensitivity

Antiepileptic hypersensitivity syndrome theoretically associated with stiripentol. See under Epilepsy p. 321 for more information.

PDF page 369

National Funding Access Decisions

PDF page 369

Safety

Interactions

→Appendix 1: antiepileptics

PDF page 369

Side Effects

PDF page 369

Pregnancy

See also Pregnancy in Epilepsy p. 321. Monitoring The dose should be monitored carefully during pregnancy and after birth, and adjustments made on a clinical basis.

PDF page 369

Breast Feeding

Present in milk in animal studies.

PDF page 369

Hepatic Impairment

Manufacturer advises avoid (no information available).

PDF page 369

Renal Impairment

Avoid—no information available.

PDF page 369

Monitoring Requirements

Perform full blood count and liver function tests prior to initiating treatment and every 6 months thereafter.

PDF page 369

Dose and formulations

Medicinal Forms

PDF page 369

Dose text by age group

Adult

Doses of up to 50 mg/kg daily in 2–3 divided

First-line fragment. Read the complete Indications and Dose section above.

PDF page 369

Age labels are extracted for navigation. Check the complete source section and current local guidance before clinical use.